NCT04689152 - Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

March 2, 2021

Primary Completion Date

August 2, 2027

Study Completion Date

January 2, 2028

Conditions

Alcoholic Cirrhosis

Interventions

BIOLOGICAL

Cellgram-LC

Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery.

Trial Locations (11)

RECRUITING

Soonchunhyang University Hospital, Bucheon-si

RECRUITING

Soonchunhyang University Hospital, Cheonan

RECRUITING

Gangwon National University Hospital, Chuncheon

RECRUITING

Hallym Univ. Medical Center, Chuncheon

RECRUITING

Gangneung Asan Hospital, Gangneung-si

RECRUITING

Eunpyeong St. Mary's Hospital, Seoul

RECRUITING

Korea University Anam Hospital, Seoul

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Soonchunhyang University Hospital, Seoul

RECRUITING

Wonju Severance Christian Hospital, Wŏnju

RECRUITING

Yongin Severance Hospital, Yŏngin

All Listed Sponsors

lead

Pharmicell Co., Ltd.

INDUSTRY